| Title |
Prognostic value of pretreatment albumin–globulin ratio in predicting long-term mortality in gastric cancer patients who underwent D2 resection
|
|---|---|
| Published in |
OncoTargets and therapy, April 2017
|
| DOI | 10.2147/ott.s99282 |
| Pubmed ID | |
| Authors |
Jianjun Liu, Shangxiang Chen, Qirong Geng, Xuechao Liu, Pengfei Kong, Youqing Zhan, Dazhi Xu |
| Abstract |
Several studies have highlighted the prognostic value of the albumin-globulin ratio (AGR) in various kinds of cancers. Our study was designed to assess whether AGR is associated with the prognosis of gastric cancer patients. A total of 507 gastric cancer patients between 2005 and 2012 were included. The AGR was defined as the ratio of serum albumin to nonalbumin and calculated by the equation: albumin/(total protein - albumin). Furthermore, AGR was divided into two groups (low and high) using the X-tile software. Survival analysis stratified by AGR groups was performed. The mean survival time for each group was 36.62 months (95% CI: 33.92-39.32) for the low AGR group and 48.95 months (95% CI: 41.93-55.96, P=0.003) for the high AGR group. Patients in the high group (AGR ≥1.93) had a significantly lower 5-year mortality in comparison with the low group (AGR <1.93) (52.4% vs 78.5%, P=0.003). The high AGR group showed obviously better overall survival than the low AGR group according to Kaplan-Meier curves (P=0.003). Multivariate analysis showed that AGR was an independent predictive factor of prognosis in gastric patients. Pretreatment AGR is a significant and independent predictive factor of prognosis. |
Mendeley readers
The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 12 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 3 | 25% |
| Unspecified | 2 | 17% |
| Student > Postgraduate | 2 | 17% |
| Researcher | 2 | 17% |
| Student > Bachelor | 1 | 8% |
| Other | 1 | 8% |
| Unknown | 1 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 42% |
| Unspecified | 2 | 17% |
| Biochemistry, Genetics and Molecular Biology | 1 | 8% |
| Chemistry | 1 | 8% |
| Physics and Astronomy | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 2 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 March 2023.
All research outputs
#3,881,305
of 25,784,004 outputs
Outputs from OncoTargets and therapy
#154
of 3,014 outputs
Outputs of similar age
#66,987
of 324,990 outputs
Outputs of similar age from OncoTargets and therapy
#8
of 92 outputs
Altmetric has tracked 25,784,004 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,014 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,990 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 92 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.